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diabolicum. (To err is human, but to
persist in the error is diabolical.)—Seneca (1)T he threat of early (i.e., within the ﬁrst30 days) stent thrombosis (ST) has accom-panied percutaneous coronary intervention
since the early days of stent intervention. The initial
attempts to mitigate that risk with aspirin, a single
antiplatelet therapy, in conjunction with parenteral
and oral anticoagulant medications, paved the way
to the dual-antiplatelet therapy (DAPT) regimen con-
sisting in a P2Y12 inhibitor and aspirin, an irreversible
cyclooxygenase-1 inhibitor (2,3). Because the vast ma-
jority of ST cases were noted to occur within the ﬁrst
weeks after stent implantation, an arbitrary 30-day to
6-week duration of DAPT has been investigated and a
30-day duration of therapy has become the standard
of care approach after uncoated stent implantation.
Yet proper stent expansion was also acknowledged
in these early days as a key factor to minimize the risk
of stent reocclusion (4), and optimal stent expansion
in some DAPT studies even a prerequisite for pa-
tients’ eligibility (2,3).
The advent of the ﬁrst-generation drug-eluting
stent (DES) has triggered renewed interest in reas-
sessing optimal DAPT duration after stent placement.
DES per se have been initially regarded more as
thrombogenic devices. This was due to their intrinsicals published in the JACC: Cardiovascular Interventions reﬂect the
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r.capability to minimize late loss and as such poten-
tially compromise stent coverage. Inﬂammation was
also noted in experimental animal models. In the
pivotal studies designed for stent approval, DAPT was
recommended for 2 (5) or 3 (6) months after sirolimus-
eluting stent placement or 6 months (7) after
paclitaxel-eluting stent placement. No safety issues
were noted early on up to at least 1 year compared
with the uncoated stents.
After several anecdotal observations that ﬁrst-
generation DES were associated with the occur-
rence of very late ST, an entity that was at that time
hardly known to exist after bare-metal stents
(BMS), the community reacted by endorsing a long-
term, or even an indeﬁnite, DAPT regimen after
DES implantation.
An extraordinary amount of scientiﬁc scrutiny has
been devoted to the safety proﬁle of ﬁrst-generation
DES (Figure 1). There has been not 1 single random-
ized, controlled study or meta-analysis of random-
ized studies showing that the risk of early, including
either acute or subacute, as well as late (from 30 days
to 1 year) ST is higher after ﬁrst-generation DES
compared with BMS (8). Some meta-analyses have
actually provided evidence that the risk of ST within
the ﬁrst year may be lower after ﬁrst-generation DES
compared with BMS (9).
On the other hand, undoubtedly, ﬁrst-generation
DES were consistently shown later to be associated
with a 4- to 5-fold higher risk of very late (i.e., after
the ﬁrst year) ST compared with BMS (8,9). This
observation corroborated the perception of increased
thrombogenicity of DES compared with BMS and
fueled the “longer the better” notion for DAPT dura-
tion in DES-treated patients (10).
First-generation DES have been entirely replaced
by newer generation devices. Emerging evidence of
superior safety with respect to ST and target vessel
myocardial infarction has been generated for some of
FIGURE 1 PubMed Citations for Stent Thrombosis
The number of PubMed citations stratiﬁed by the year of publication using the
search term “stent thrombosis.”
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1115the newly introduced devices compared with ﬁrst-
generation DES (11–13). Importantly, most of these
second-generation stents were approved in non-
inferiority trials compared with ﬁrst-generation DES.
Therefore, few studies have directly compared
second-generation DES with BMS. There is a growing
literature suggesting that at least some second-
generation devices may be safer not only when
compared with ﬁrst-generation but also with the
corresponding BMS counterparts (13–15).
Still, the last chapter of the ﬁrst-generation DES
saga needs to be written, including answering the
question of how long will the enhanced risk of ST
remain such after implantation as well as identifying
how to best treat patients presenting with ST.
Unlike the vast amount of rigorous statistics
generated on the incidence and distribution of ST
events over time after ﬁrst-generation devices, the
complete absence of randomized data to inform on
the best management strategy for patients presenting
with ST is notable.SEE PAGE 1105In this issue of JACC: Cardiovascular Interventions,
Armstrong et al. (16) report on a combined retro-
spective and prospective observational California
registry of angiographic deﬁnite ST at 5 academic
hospitals from 2005 to 2013. The entry criterion was
the occurrence of a deﬁnite ST, which was observed
in 221 patients of an unknown number of patients at
risk. With the important caveat of not knowing the
exact timing of ﬁrst ST event after the index proce-
dure for each stent type, 104 (47%) patients had
received a ﬁrst-generation DES, 51 (23%) a BMS, and
19 (9%) a second-generation DES. After a median
follow-up of 3.3 years, deﬁnite or probable recurrent
ST (rST) developed in 29 patients, whereas 19 pre-
sented with angiographic deﬁnite rST.
The cumulative hazard ratio of deﬁnite or probable
rST was 16% at 1 year and 24% at 5 years. The
cumulative hazard ratio of angiographic deﬁnite rST
was 11% at 1 year and 20% at 5 years. Taken together,
these ﬁndings conﬁrm the high risk of ST recurrences
after the occurrence of the ﬁrst ST and call for dedi-
cated treatment protocols for patients presenting
with ST.
A second key piece of information that is
conveyed by this important analysis is that the risk
of recurrence is highest in the ﬁrst few months after
the ﬁrst event, but it does not abate entirely over
time. This study suggests that w50% of events are
clustered within the ﬁrst year after reintervention,
whereas the remaining 50% of events occur from
the second to the ﬁfth year of follow-up. Thisobservation carries important implications with
respect to the duration of secondary preventive
measures in this relatively small yet challenging pa-
tient population.
Two procedural and 1 post-procedural manage-
ment strategies deserve speciﬁc comments.
At the time of the index ST event, intravascular
ultrasound was used in w1 in every 4 patients. Given
the well-known capability of intravascular ultrasound
to shed new light on the reasons underlying an ST
event, including undersizing, malapposition, and re-
sidual untreated vessel dissection, I tend to believe
that an intravascular imaging modality should be
offered to all patients experiencing this catastrophic
scenario. Importantly, large proximal vessel diameter
and initial ST at bifurcation were identiﬁed as inde-
pendent rSTs. These ﬁndings emphasize the need for
optimal stent deployment and apposition as a key
procedural factor to mitigate the risk of recurrences.
These observations are consistent with the Dutch
stent thrombosis registry that showed undersizing to
be among the most important predictors of ST, sec-
ond only to clopidogrel discontinuation within the
ﬁrst 30 days (17).
A second remarkable procedural aspect is that >1
patient in every 2 underwent restenting in the
setting of the ﬁrst ST event. New stent deploy-
ment was not identiﬁed as a predictor of rST in
this registry. Yet, given the relatively low number of
recurrent ST events, caution should be used in in-
terpreting current ﬁndings, especially considering
that the reasons for restenting were not collected. It
is noteworthy that 2 independent studies previously
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1116suggested an association between restenting and
mortality after the ﬁrst ST event (17,18). While
acknowledging that only a prospective, randomized,
controlled trial could conclusively ascertain the risk-
beneﬁt ratio of restenting, based on available retro-
spective data (17,18), additional stent implantation
in the setting of ST should probably be restricted to a
bailout strategy. Because stent underexpansion or
undersizing is known to frequently contribute to
ST, optimal, ideally imaging-guided, further expan-
sion of the originally implanted stent should most
likely be the goal of reintervention beyond vessel
recanalization.
The majority of patients were discharged on
aspirin and clopidogrel in this registry. This reﬂects
the limited availability of more potent and consistent
P2Y12 inhibitors during the study period. Both pra-
sugrel and ticagrelor have been shown to be associ-
ated with a signiﬁcant reduction of deﬁnite and
deﬁnite or probable ST compared with clopidogrel
(19,20). Moreover, both studies indicated that the
number of recurrent events is also signiﬁcantly
decreased by treatment with ticagrelor or prasugrelcompared with clopidogrel. Hence, the use of clopi-
dogrel after ST cannot be regarded as an effective
treatment option. Considering the long-term risk of
recurrence after the ﬁrst ST, it may be reasonable in
this highly selected high-risk patient population to
make any effort to maintain DAPT in the very long
term, if tolerated.
Finally, all attempts should be made to retrieve
any possible driver of ST, including inspection of the
index procedure and careful assessment of a patient’s
history, focusing on compliance with antiplatelet
therapy and appraisal of possible triggers, which also
comprise prothrombotic morbidity and concomitant
medications.
If ST avoidance is the mind-set of every interven-
tional cardiologist during every stent procedure,
prevention of recurrences requires even more
commitment from all potential stakeholders.
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